Education

Bachelor of Pharmacy: NMIMS Univeristy Mumbai, India, 2015

MS in Pharmaceutical Sciences with empasis in drug delivery systems: Northeastern University Boston, Massachusettes, 2017

Research and Practice Interests

Melanoma drug resistance

Publications

Published Abstracts

Long Yuan, Rosalin Mishra, Hima Patel, Samar Alanazi, Joan T. Garrett (04-2018. ) Reactive oxygen species scavenger extends the efficacy of BRAF inhibitors in BRAF-mutant melanoma .[Abstract]Cancer Research, 78 ,Supplement 13Co-Author

Rosalin Mishra, Samar Alanazi, Hima Patel, Long Yuan, Joan T. Garrett (06-2019. ) Role of her3 signaling pathways in er+ and her2+ breast cancers .[Abstract]Cancer Research, 79 , -Supplement 13 Co-Author

Hima Patel, Rosalin Mishra, Joan T. Garrett (06-2019. ) Resistance to BRAF and MEK inhibitors in BRAF V600E mutant melanoma .[Abstract]Cancer Research, 79 , -Supplement 13 Author

Rosalin Mishra, Hima Patel, Haizhou Zhu, Aaron White, Long Yuan, Samar Alanazi, Kurt Hodges, Edward J Merino, Joan T Garrett (2020. ) Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer .[Abstract]Cancer Research, 80 (4 ) ,Co-Author

Yuan, L.; Mishra, R.; Patel, H.; Alanazi, S.; Wei, X.; Garrett, J.T. (2020. ) The Role Of SOD2 and ROS In BRAF/MEK Inhibitor Resistance In BRAF Mutant Melanoma .[Abstract]Co-Author

Peer Reviewed Publications

Hima Patel, Jagruti Vaghela (2015. ) HYDROCOLLOIDAL SYSTEMS BASED ON POLYMERIC MATERIAL FOR DRUG TARGETING – A REVIEW . Indo American Journal of Pharmaceutical Research, , 5 (2 ) ,765-771

Rachana Somaiya, Hima Patel, Mukesh Nandave (2015. ) Potential Future Therapies of Myocardial Ischemia Reperfusion Injury .Indian Journal of Cardio Biology & Clinical Sciences, , 2 (1 ) ,

Rosalin Mishra, Hima Patel, Long Yuan, Joan T. Garrett (04-2018. ) Role of Reactive Oxygen Species and Targeted Therapy in Metastatic Melanoma.Cancer Research Frontiers, , 4 (1 ) ,101-130 More Information

Rosalin Mishra, Hima Patel, Samar Alanazi, Long Yuan, Joan T. Garrett (05-2018. ) HER3 signaling and targeted therapy in cancer.Oncology Reviews, , 12 (355 ) , More Information

Long Yuan, Rosalin Mishra, Hima Patel, Safanas Abdulsalam, Kenneth D. Greis, Ana Luisa Kadekaro, Edward J. Merino, Joan T. Garrett (11-2018. ) Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma.Journal of Cancer, , 9 (24 ) ,4665-4676 More Information

Patel, Hima; Yacoub, Nour; Mishra, Rosalin; White, Aaron; Yuan, Long; Alanazi, Samar; Garret, Joan. T. (2020. ) Current Advances in the Treatment of BRAF-Mutant Melanoma.Cancers (Basel), , 12 (2 ) ,482 More Information

Yuan, L.; Mishra, R.; Patel. H.; Alanazi, S.; Wei, Xin.; Zhijun, M.; Garrett, J.T. (2020. ) BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels.Cancers (Basel), , 12 (6 ) ,1661 More Information

Presentations

Poster Presentations

Long Yuan, Rosalin Mishra, Hima Patel, Samar Alanazi, Joan T. Garrett (04-2018. ) Reactive oxygen species scavenger extends the efficacy of BRAF inhibitors in BRAF-mutant melanoma .AACR Annual Meeting, Chicahi, IL. . Conference. . Level:International

Rosalin Mishra, Samar Alanazi, Hima Patel, Long Yuan, Joan T. Garrett (03-2019. ) Role of her3 signaling pathways in er+ and her2+ breast cancers .AACR Annual Meeting 2019, Atlanta, GA. . Conference. . Level:International

Hima Patel, Rosalin Mishra, Joan T. Garrett (03-2019. ) Resistance to BRAF and MEK inhibitors in BRAF V600E mutant melanoma .AACR Annual Meeting 2019, Atlanta, GA. . Conference. . Level:International

Hima Patel, Rosalin Mishra, Long Yuan, Samar Alanazi, Joan T. Garrett (10-2019. ) Resistance to BRAF and MEK inhibitors in BRAF mutant melanoma .S2TC Research Symposium, Cincinnati, OH. . UC. . Level:University

Rosalin Mishra, Hima Patel, Haizhou Zhu, Aaron White, Long Yuan, Samar Alanazi, Kurt Hodges, Edward J Merino and Joan T Garrett (2020. ) Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer .Henry B. Gonzalez Convention Center, San Antonio, TX. . Professional Meeting. . Level:National

Honors and Awards

02-2019 Rho Chi, Beta Nu Chapter, University of Cincinnati Status:Recipient Level:University

09-2018 Golden Key International Honour Society Status:Recipient Level:International

Professional Affiliation

07-2015 -07-2017: American Association of Pharmaceutical Scientist Northeastern University,

08-2016 -08-2019: American Association for Advancement of Science

08-2018 -08-2019: American Association of Pharmaceutical Scientist University of Cincinnati

11-2018: American Association of Cancer Research

04-2016 -04-2017: International Society for Pharmaceutical Engineering Boston